Is Johnson & Johnson (JNJ) The Most Profitable Healthcare Stock To Buy?

Group 1 - Johnson & Johnson (NYSE: JNJ) is recognized as one of the most profitable healthcare stocks, with TD Cowen raising its price target from $222 to $250, indicating a potential upside of approximately 14% [1] - The company's fourth quarter results exceeded market estimates, reporting $24.6 billion in revenue, which has led several analysts to update their outlooks positively [3] - TD Cowen anticipates that Johnson & Johnson's Pharmaceutical and Medical Devices segments will continue to grow, uplifting consensus revenue and EPS forecasts [2] Group 2 - Johnson & Johnson operates in two main segments: Innovative Medicine and MedTech, providing healthcare products globally since its founding in 1886 [4] - BofA Securities has also slightly increased its price target for Johnson & Johnson from $220 to $221, maintaining a Neutral rating, citing solid financial results driven by growth factors, particularly currency movements [3]